Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 48, 6753-6757, December 1, 1988]
© 1988 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yao, M.
Right arrow Articles by Kubota, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yao, M.
Right arrow Articles by Kubota, Y.

Enhanced Expression of c-myc and Epidermal Growth Factor Receptor (C-erbB-1) Genes in Primary Human Renal Cancer1

Masahiro Yao, Taro Shuin2, Hiroshi Misaki and Yoshinobu Kubota

Department of Urology, Yokohama City University School of Medicine, 3-46 Urafune-cho, Minami-ku, Yokohama, Kanagawa, 232, Japan

We have analyzed the expression of 12 protooncogenes, c-Ha-ras, c-Ki-ras, N-ras, c-myc, N-myc, c-fos, c-abl, c-fes, c-fms, c-raf, c-erbB-1, and c-erbB-2, in tissues of human renal cell carcinomas and in adjacent normal kidneys. Comparative densitometry of Northern blot analyses demonstrated enhanced level of c-myc gene expression, i.e., greater than threefold increase over normal kidney tissues, in 11 of 15 (73%) of the tumors examined. Increased levels of c-erbB-1 mRNA were likewise observed in seven of 15 (47%). Interestingly, many of the tumors exhibiting elevated levels of c-erbB-1 revealed increases in c-myc mRNA levels. However, Southern blot analysis failed to detect gene amplification or rearrangement in the tumors with elevated levels of c-myc and/or c-erbB-1. Although N-ras, c-fos, and c-raf gene transcripts were detected in both malignant and normal tissues, differences in these protooncogene expressions were not found between the carcinomas and normal kidneys. Significant elevations of expression were found in one of 16 cases of each for c-Ha-ras and c-fms, whereas expression of c-Ki-ras, N-myc, c-fes, c-abl, or c-erbB-2 could not be detected in any of the tissues surveyed. These results suggested that activation of c-myc and c-erbB-1 genes may be involved in the development of human renal cell carcinomas.

1 This work is supported by Grant-in-Aid (Grants 61570711 and 62771199) from the Ministry of Education, Science and Culture of Japan.

2 To whom requests for reprints should be addressed.

Received 7/ 7/87. Revised 8/ 8/88. Accepted 9/ 2/88.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
H. Sultmann, A. v. Heydebreck, W. Huber, R. Kuner, A. Buness, M. Vogt, B. Gunawan, M. Vingron, L. Fuzesi, and A. Poustka
Gene Expression in Kidney Cancer Is Associated with Cytogenetic Abnormalities, Metastasis Formation, and Patient Survival
Clin. Cancer Res., January 15, 2005; 11(2): 646 - 655.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. A. Dawson, C. Guo, R. Zak, B. Dorsey, J. Smoot, J. Wong, and A. Hussain
A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma
Clin. Cancer Res., December 1, 2004; 10(23): 7812 - 7819.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. K. Rowinsky, G. H. Schwartz, J. A. Gollob, J. A. Thompson, N. J. Vogelzang, R. Figlin, R. Bukowski, N. Haas, P. Lockbaum, Y.-P. Li, et al.
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer
J. Clin. Oncol., August 1, 2004; 22(15): 3003 - 3015.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
H. Moch, P. Schraml, L. Bubendorf, M. Mirlacher, J. Kononen, T. Gasser, M. J. Mihatsch, O. P. Kallioniemi, and G. Sauter
High-Throughput Tissue Microarray Analysis to Evaluate Genes Uncovered by cDNA Microarray Screening in Renal Cell Carcinoma
Am. J. Pathol., April 1, 1999; 154(4): 981 - 986.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. J. Motzer, N. H. Bander, and D. M. Nanus
Renal-Cell Carcinoma
N. Engl. J. Med., September 19, 1996; 335(12): 865 - 875.
[Full Text] [PDF]


Home page
Genome Res.Home page
J. M. Boer, W. K. Huber, H. Sultmann, F. Wilmer, A. von Heydebreck, S. Haas, B. Korn, B. Gunawan, A. Vente, L. Fuzesi, et al.
Identification and Classification of Differentially Expressed Genes in Renal Cell Carcinoma by Expression Profiling on a Global Human 31,500-Element cDNA Array
Genome Res., November 1, 2001; 11(11): 1861 - 1870.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1988 by the American Association for Cancer Research.